Trials / Completed
CompletedNCT02674321
A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)
A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Auspex Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety, tolerability and preliminary efficacy of SD-809 in the treatment of motor and phonic tics of Tourette Syndrome and to evaluate the pharmacokinetic of SD-809 and its metabolites.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SD-809 |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2016-02-04
- Last updated
- 2021-11-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02674321. Inclusion in this directory is not an endorsement.